RDA Financial Network Has $895,000 Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

RDA Financial Network increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.2% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,771 shares of the company’s stock after purchasing an additional 357 shares during the quarter. RDA Financial Network’s holdings in IDEXX Laboratories were worth $895,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in IDXX. Nordea Investment Management AB lifted its stake in IDEXX Laboratories by 15.5% in the 1st quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after purchasing an additional 1,839 shares during the last quarter. Manning & Napier Advisors LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $20,418,000. First Hawaiian Bank acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $982,000. Meyer Handelman Co. bought a new stake in IDEXX Laboratories in the 1st quarter valued at $2,155,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in IDEXX Laboratories by 13.8% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after purchasing an additional 1,453 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.5 %

NASDAQ:IDXX traded down $2.59 during mid-day trading on Tuesday, hitting $475.41. 282,707 shares of the company’s stock were exchanged, compared to its average volume of 466,428. The company has a current ratio of 1.37, a quick ratio of 1.03 and a debt-to-equity ratio of 0.33. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a 50 day simple moving average of $488.46 and a 200-day simple moving average of $493.17. The firm has a market capitalization of $39.26 billion, a P/E ratio of 46.27, a PEG ratio of 4.14 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $2.67 EPS. IDEXX Laboratories’s quarterly revenue was up 6.4% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on IDXX. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.